Becton Dickinson (BDX) AI Stock Analysis

• Market Cap: $57.97B
• Dividend Yield: 2.13%
• Average Volume (3M): 1.43M
• Price to Earnings (P/E): 35.0
• Beta (1Y): 0.39
• Revenue Growth: 8.23%
• EPS Growth: -2.04%
• Country: US
• Employees: 70,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 3.96
• Shares Outstanding: 284,908,080
• 10 Day Avg. Volume: 1,780,964
• 30 Day Avg. Volume: 1,427,997
• PEG Ratio: -47.00
• Price to Book (P/B): 2.11
• Price to Sales (P/S): 2.46
• P/FCF Ratio: 20.09
• Enterprise Value/Market Cap: 1.32
• Enterprise Value/Revenue: 3.50
• Enterprise Value/Gross Profit: 7.70
• Enterprise Value/Ebitda: 15.41
• 1Y Price Target: $207.14
• Price Target Upside: 1.80% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: $219.00 ▲(7.63% Upside)

The score is driven primarily by stable financial performance (healthy margins, improving leverage, and strong cash generation) and a generally positive—but cautious—FY26 earnings outlook with clear margin and cost actions. This is tempered by a neutral technical picture in the near term and a relatively high valuation (P/E 34.72) that reduces upside if growth slows under the cited headwinds.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, enhancing long-term financial stability.

Operational Efficiency

Improved operational efficiency and margin expansion reflect strong management practices, supporting sustainable profitability.

Strategic Initiatives

Strategic initiatives to cut costs and focus on high-growth areas can drive future growth and enhance competitive positioning.

Negative Factors

Declining Vaccine Demand

Reduced vaccine demand may lead to lower revenue in a significant business segment, impacting overall growth prospects.

Challenges in China

Regulatory challenges in China could hinder growth in a key market, affecting revenue and market expansion opportunities.

Alaris Headwinds

Headwinds from Alaris capital installations may dampen growth, requiring strategic adjustments to mitigate impact.

Becton Dickinson Business Overview & Revenue Model

Company Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

How the Company Makes Money

BDX generates revenue through the sale of its diverse product offerings across its three main segments. The BD Medical segment, which provides medical devices and supplies, contributes significantly to the company's revenue through sales to hospitals and healthcare facilities. BD Life Sciences generates income from its diagnostic systems and reagents, catering to laboratories and healthcare providers that require testing solutions. BD Interventional focuses on products used in minimally invasive procedures, contributing to revenue through partnerships with hospitals and surgical centers. Additionally, BDX capitalizes on long-term contracts and collaborations with healthcare institutions, ensuring a steady revenue stream. The company also invests in research and development to innovate and expand its product lines, which can enhance its market position and drive future earnings.

Becton Dickinson Financial Statement Overview

Summary

Solid fundamentals with modest TTM revenue growth (2.12%) and healthy profitability (gross margin 45.44%, EBITDA margin 22.70%). Leverage is well-managed (debt-to-equity 0.34), but ROE is relatively low (5.11%) and net margin slipped to 7.68%. Cash generation is strong (operating cash flow to net income 3.04) with positive FCF growth, though FCF conversion softened (FCF to net income 0.78).

Income Statement

Becton Dickinson shows a solid revenue growth rate of 2.12% in the TTM, with a stable gross profit margin of 45.44%. However, the net profit margin has slightly decreased to 7.68% from 8.45% in the previous year. The EBIT and EBITDA margins remain healthy at 11.42% and 22.70%, respectively, indicating strong operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.34 in the TTM, indicating better leverage management compared to the previous year. Return on equity is at 5.11%, showing a slight decline, which could be a concern for investors. The equity ratio stands at 45.89%, reflecting a stable financial position.

Cash Flow

Free cash flow growth is positive at 4.71% in the TTM, which is a good sign. The operating cash flow to net income ratio is strong at 3.04, suggesting efficient cash generation. However, the free cash flow to net income ratio has slightly decreased to 0.78, indicating a need for improvement in cash flow conversion.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	21.84B	21.84B	20.18B	19.37B	18.87B	19.13B
Gross Profit	9.92B	9.92B	9.13B	8.17B	8.48B	8.63B
EBITDA	4.96B	4.96B	4.82B	4.40B	4.41B	4.39B
Net Income	1.68B	1.68B	1.71B	1.48B	1.78B	2.09B
Balance Sheet
Total Assets	55.33B	55.33B	57.29B	52.78B	52.93B	53.88B
Cash, Cash Equivalents and Short-Term Investments	859.00M	859.00M	2.16B	1.42B	1.01B	2.29B
Total Debt	19.18B	19.18B	20.11B	15.88B	16.07B	17.61B
Total Liabilities	29.94B	29.94B	31.40B	26.98B	27.65B	30.20B
Stockholders Equity	25.39B	25.39B	25.89B	25.80B	25.28B	23.68B
Cash Flow
Free Cash Flow	2.67B	2.67B	3.07B	2.12B	1.66B	3.42B
Operating Cash Flow	3.43B	3.43B	3.80B	2.99B	2.63B	4.65B
Investing Cash Flow	-818.00M	-818.00M	-5.51B	-716.00M	-3.23B	-1.88B
Financing Cash Flow	-3.62B	-3.62B	2.09B	-1.96B	-591.00M	-3.31B

Becton Dickinson Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 203.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDX, the sentiment is Positive. The current price of 203.48 is above the 20-day moving average (MA) of 203.39, above the 50-day MA of 197.76, and above the 200-day MA of 185.50, indicating a bullish trend. The MACD of 1.60 indicates Positive momentum. The RSI at 54.24 is Neutral, neither overbought nor oversold. The STOCH value of 50.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BDX.

Becton Dickinson Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ISRG	78 Outperform	$178.74B	63.98	16.62%	―	22.18%	21.37%
RMD	78 Outperform	$37.70B	25.53	25.68%	0.92%	9.36%	29.56%
BDX	68 Neutral	$57.97B	34.99	6.54%	2.13%	8.23%	-2.04%
WST	68 Neutral	$16.63B	34.23	16.94%	0.32%	4.90%	-0.26%
HOLX	63 Neutral	$16.73B	31.09	10.86%	―	1.74%	-25.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BAX	47 Neutral	$10.32B	-38.49	-4.70%	2.75%	-21.20%	-325.40%

Becton Dickinson Corporate Events

Becton Dickinson adopts executive severance plan, equity increase

On January 27, 2026, BD’s board adopted a new Executive Severance Plan that standardizes severance benefits for senior management, including the CEO, executive leadership team, business unit presidents and other eligible executives who are terminated without cause, excluding cases such as death, disability, cause, voluntary resignation, retirement or certain divestiture-related terminations. The plan offers tiered cash severance based on salary and target bonus levels, pro-rated target bonuses for the year of termination, a lump-sum COBRA-related payment for continued health coverage, and up to nine months of outplacement services, all contingent on a general release of claims, compliance with post-employment covenants and the company’s clawback policies, signaling a more formalized approach to executive transitions and retention. At its 2026 Annual Meeting on January 27, 2026, shareholders also approved an increase of 3,935,000 shares under BD’s 2004 Employee and Director Equity-Based Compensation Plan, re-elected all director nominees, ratified Ernst & Young as the independent auditor for fiscal 2026 and backed executive compensation on an advisory basis, underscoring broad investor support for the company’s governance, pay practices and long-term equity incentive framework.

The most recent analyst rating on (BDX) stock is a Hold with a $205.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.